Phase 1, Open-Label, Dose Escalation, Safety, and Pharmacokinetics Study of ME-344 as a Single Agent in Patients With Refractory Solid Tumors

BACKGROUND: The current phase 1, open-label, dose escalation study was conducted to establish the safety, tolerability, pharmacokinetic profile, and preliminary antitumor activity of the novel mitochondrial inhibitor ME-344 in patients with refractory solid tumors. METHODS: Patients with refractory...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Bendell, Johanna C, Patel, Manish R, Infante, Jeffrey R, Kurkjian, Carla D, Jones, Suzanne F, Pant, Shubham, Burris, Howard A, Moreno, Ofir, Esquibel, Vanessa, Levin, Wendy, Moore, Kathleen N
Formato: Artigo
Idioma:Inglês
Publicado em: BlackWell Publishing Ltd 2015
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4406150/
https://ncbi.nlm.nih.gov/pubmed/25411085
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.29155
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados